[0007e] In yet another aspect, the present disclosure refers to the compound disclosed herein for use in therapy.

[0007f] In another aspect, the present disclosure refers to the compound disclosed herein for use in inducing therapeutic weight loss.

[0007g] In yet another aspect, the present disclosure refers to the compound disclosed herein for use in the treatment of Type 2 diabetes.

[0007h] In a further aspect, the present disclosure refers to the compound disclosed herein for use in the treatment of obesity.

[0007i] In yet another aspect, the present disclosure refers to the compound disclosed herein for use in the treatment of dyslipidemia.

[0007j] In another aspect, the present disclosure refers to the compound disclosed herein for use in the treatment of NASH.

[0007k] In yet another aspect, the present disclosure refers to the use of a compound disclosed herein, in the manufacture of a medicament for inducing therapeutic weight loss.

[0007l] In a further aspect, the present disclosure refers to the use of a compound disclosed herein, in the manufacture of a medicament for the treatment of Type 2 diabetes.

[0007m] In yet another aspect, the present disclosure refers to the use of a compound disclosed herein, in the manufacture of a medicament for the treatment of obesity

[0007n] In another aspect, the present disclosure refers to the use of a compound disclosed herein, in the manufacture of a medicament for the treatment of dyslipidemia.

[0007o] In yet another aspect, the present disclosure refers to the use of a compound disclosed herein, in the manufacture of a medicament for the treatment of NASH.

[0007p] In yet another aspect, the present disclosure refers to the use of a compound disclosed herein or the composition disclosed herein, in the manufacture of a medicament for inducing therapeutic weight loss in a patient, for treating Type 2 diabetes, obesity, NASH and/or dyslipidemia, wherein the medicament is to be administered to a patient in need thereof once per week.

CLAIMS

The invention claimed is:

1. A compound comprising SEQ ID NO:2.

2. A compound consisting of SEQ ID NO:2.

3. A homodimer comprising two compounds of Claim 1 or 2, wherein the compounds are linked via at least one interchain disulfide bond between a cysteine residue of the first compound and a cysteine residue of the second compound.

4. A pharmaceutical composition comprising the compound of Claims 1-3 and one or more pharmaceutically acceptable excipients.

5. The compound of Claims 1-3 for use in therapy.

6. The compound of Claims 1-3 for use in inducing therapeutic weight loss.

7. The compound of Claims 1-3 for use in the treatment of Type 2 diabetes.

8. The compound of Claims 1-3 for use in the treatment of obesity.

9. The compound of Claims 1-3 for use in the treatment of dyslipidemia.

10. The compound of Claims 1-3 for use in the treatment of NASH.

11. Use of a compound of Claims 1-3, in the manufacture of a medicament for inducing therapeutic weight loss.

12. Use of a compound of Claims 1-3, in the manufacture of a medicament for the treatment of Type 2 diabetes.

13. Use of a compound of Claims 1-3, in the manufacture of a medicament for the treatment of obesity.

14. Use of a compound of Claims 1-3, in the manufacture of a medicament for the treatment of dyslipidemia.

15. Use of a compound of Claims 1-3, in the manufacture of a medicament for the treatment of NASH.

16. Use of a compound of Claims 1-3 or the composition of Claim 4, in the manufacture of a medicament for inducing therapeutic weight loss in a patient, treating Type 2 diabetes, obesity, NASH and/or dyslipidemia, wherein the medicament is to be administered to a patient in need thereof once per week.